Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Aug;9(8):2308-2310.
doi: 10.21037/jtd.2017.07.75.

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy

Theodosios D Filippatos  1 , Moses S Elisaf  1
Affiliations
Editorial

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy

Theodosios D Filippatos et al. J Thorac Dis. 2017 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: This editorial was conducted independently. MS Elisaf reports personal fees from Astra-Zeneca, grants and personal fees from MSD, personal fees from PFIZER, ABBOTT, Sanofi-Aventis, Boehringer Ingelheim, Eli-Lilly and GSK. TD Filippatos has given talks and attended conferences sponsored by various pharmaceutical companies, including Bristol-Myers Squibb, Pfizer, Lilly, Abbott, Amgen, AstraZeneca, Novartis, Vianex, Teva and MSD.

Comment on

  • Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
    Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Lincoff AM, et al. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Clinical Trial.

References

    1. Filippatos TD, Klouras E, Barkas F, et al. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev Cardiovasc Ther 2016;14:953-62. 10.1080/14779072.2016.1189327 - DOI - PubMed
    1. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. 10.1056/NEJMoa0706628 - DOI - PubMed
    1. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99. 10.1056/NEJMoa1206797 - DOI - PubMed
    1. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med 2017;376:1933-42. 10.1056/NEJMoa1609581 - DOI - PubMed
    1. Nicholls SJ, Ray KK, Ballantyne CM, et al. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis 2017;261:12-8. 10.1016/j.atherosclerosis.2017.04.008 - DOI - PubMed

LinkOut - more resources